• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sean Whooley

Canadian university set for Phase 2 human trials of inhaled COVID-19 vaccine

January 20, 2023 By Sean Whooley

Researchers at McMaster University in Canada announced that they received $8.2 million from the Canadian Institutes of Health Research (CIHR). Fiona Smaill picked up $8.2 million to advance an inhaled COVID-19 vaccine through to Phase 2 human trials. The trials will evaluate the safety and immunogenicity of the next-generation vaccine delivered by inhaled aerosol. Her […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, McMaster University

CardioRenal Systems wins FDA breakthrough nod for RenalGuard Therapy device

January 20, 2023 By Sean Whooley

CardioRenal Systems RenalGuard

CardioRenal Systems announced today that it received FDA breakthrough device designation for its RenalGuard Therapy device. Milford, Massachusetts-based CardioRenal Systems designed the device for preventing acute kidney injury (AKI). It’s for patients at risk for cardiac surgery-associated AKI. RenalGuard protects the kidneys with personalized, active hydration. The system maximizes urine output while balancing hydration. It […]

Filed Under: Cardiovascular, Drug-Device Combinations, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: CardioRenal Systems

Akili lays off 46 workers

January 18, 2023 By Sean Whooley

Akili EndeavorRx video game for ADHD

Akili announced that its board of directors approved an operating plan for 2023 that includes a 30% workforce reduction. The Boston-based digital therapeutic developer’s reduction reaches across different areas and functions. In total, 30% of Akili’s workforce amounts to 46 employees. The company communicated the decision to employees on Jan. 12 and expects to complete […]

Filed Under: Business/Financial News, Neurological, Pediatrics, Technology Tagged With: Akili

Eitan Medical opens new manufacturing facility for wearable drug delivery platform

January 17, 2023 By Sean Whooley

Eitan Medical Sorrel wearable drug delivery system

Eitan Medical announced today that it opened a new manufacturing facility at its headquarters to support drug delivery device production. Netanya, Israel-based Eitan intends for the facility to manufacture its Sorrel wearable drug delivery platform. That includes multiple device configurations, such as vial- and cartridge-based wearable injectors. On-site manufacturing supports Eitan’s production scale for its […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Technology Tagged With: Eitan Medical

How Dexcom aims to extend its mission beyond diabetes

January 13, 2023 By Sean Whooley

Dexcom CEO Kevin Sayer

CEO Kevin Sayer explains how, following the launch of the next-generation Dexcom G7, the company is looking toward the future. Dexcom (Nasdaq:DXCM) ended 2022 strong, receiving FDA clearance for its next-generation G7 continuous glucose monitor (CGM). With a U.S. launch imminent, the company could keep its efforts centered on the diabetes space. Instead, the company […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Technology Tagged With: Dexcom

Oramed may discontinue oral insulin activity for type 2 diabetes after trial misses endpoints

January 12, 2023 By Sean Whooley

Oramed Logo

Oramed Pharmaceuticals (Nasdaq:ORMP) announced that top-line Phase 3 trial results for its oral insulin candidate missed its endpoints. The Phase 3, randomized, double-blind, placebo-controlled trial compared the efficacy of ORMD-0801 to placebo. It evaluated patients with type 2 diabetes at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control. Those patients were […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Pharmaceuticals Tagged With: oramedpharmaceuticals

Diabeloop, EOFlow partner on wearable automated insulin delivery in Europe

January 12, 2023 By Sean Whooley

EOFlow EOPatch insulin patch

Diabeloop and EOFlow announced that they partnered to offer the latter’s EOPatch system with automated insulin delivery in Europe. This partnership combines the EOPatch, a third-party continuous glucose monitor (CGM) and Diabeloop’s automated insulin delivery algorithm. They all integrate into Diabeloop’s currently under-development smartphone app. Paris-based Diabeloop said in a news release that they also […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Diabeloop, eoflow

This AI-based smartphone app helps diabetes patients manage blood sugar

January 11, 2023 By Sean Whooley

Oregon Health & Science University OHSU AI smartphone app diabetes

Oregon Health & Science University (OHSU) combined AI and diabetes experts to develop a smartphone app to help manage blood sugar levels. OHSU biomedical engineer Peter Jacobs and OHSU endocrinologist Dr. Leah Wilson lead this project. They plan to organize a randomized clinical trial to evaluate an enhanced app used in concert with diabetes education […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Diabetes, Oregon Health & Science University (OHSU)

Vero Biotech raises $30M for tankless nitric oxide delivery system

January 11, 2023 By Sean Whooley

Vero Biotech Genosyl iNO delivery system

Vero Biotech announced today that it raised $30 million to support its Genosyl inhaled nitric oxide (iNO) delivery system. The financing comes just days after the company received FDA approval for Genosyl. The third-generation Genosyl delivery system features faster dosing, simpler workflow and operational efficiency. Petrichor, a healthcare-dedicated growth capital provider, led the financing. Atlanta-based […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pediatrics, Pharmaceuticals, Respiratory Tagged With: Vero Biotech

Tandem Diabetes Care expects double-digit revenue growth in 2023

January 11, 2023 By Sean Whooley

Tandem Diabetes Care

Tandem Diabetes Care (Nasdaq:TNDM) announced preliminary fourth-quarter results and offered expectations for the coming year. San Diego-based Tandem expects sales to total $221 million, coming in $11 million higher than the same quarter last year. Wall Street analysts expected $221.6 million in revenues. However, the automated insulin delivery technology developer noted that its adjusted sales […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Tandem Diabetes Care

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 74
  • Page 75
  • Page 76
  • Page 77
  • Page 78
  • Interim pages omitted …
  • Page 170
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS